Suppr超能文献

PLA2R1 通过激活 JAK2 介导肿瘤抑制。

PLA2R1 mediates tumor suppression by activating JAK2.

机构信息

Authors' Affiliations: Inserm U1052, Centre de Recherche en Cancérologie de Lyon; CNRS UMR5286; Centre Léon Bérard; Université de Lyon, Lyon; UMR8161, CNRS/Universités de Lille 1 et 2; Institut de Pharmacologie Moléculaire et Cellulaire, UMR7275, CNRS and Université de Nice-Sophia Antipolis, Valbonne; INSERM U916, Bergonié Cancer Institute, Université Bordeaux, Bordeaux; and Institut de Pathologie, CHRU, Faculté de Médecine, Université de Lille; INSERM U837, Jean-Pierre Aubert Research Center, Team 5, Lille; Department of Medicine, University of Washington, Seattle, Washington.

出版信息

Cancer Res. 2013 Oct 15;73(20):6334-45. doi: 10.1158/0008-5472.CAN-13-0318. Epub 2013 Sep 5.

Abstract

Little is known about the physiological role of the phospholipase A2 receptor (PLA2R1). PLA2R1 has been described as regulating the replicative senescence, a telomerase-dependent proliferation arrest. The downstream PLA2R1 signaling and its role in cancer are currently unknown. Senescence induction in response to activated oncogenes is a failsafe program of tumor suppression that must be bypassed for tumorigenesis. We now present evidence that PLA2R1 functions in vitro as a tumor suppressor, the depletion of which is sufficient to escape oncogene-induced senescence (OIS), thereby facilitating oncogenic cell transformation. Furthermore, mice that are genetically deficient in PLA2R1 display increased sensitivity to RAS-induced tumorigenesis by facilitating OIS escape, highlighting its physiological role as a tumor suppressor. Unexpectedly, PLA2R1 activated JAK2 and its effector signaling, with PLA2R1-mediated inhibition of cell transformation largely reverted in JAK2-depleted cells. This finding was unexpected as the JAK2 pathway has been associated mainly with protumoral functions and several inhibitors are currently in clinical trials. Taken together, our findings uncover an unanticipated tumor suppressive role for PLA2R1 that is mediated by targeting downstream JAK2 effector signaling.

摘要

目前对于磷脂酶 A2 受体 (PLA2R1) 的生理作用知之甚少。PLA2R1 被描述为调节复制性衰老,这是一种端粒酶依赖性增殖停滞。目前尚不清楚 PLA2R1 的下游信号及其在癌症中的作用。对激活的癌基因的衰老诱导是肿瘤抑制的故障安全程序,必须被绕过以促进肿瘤发生。我们现在提供的证据表明,PLA2R1 在体外作为肿瘤抑制因子发挥作用,其缺失足以逃避癌基因诱导的衰老 (OIS),从而促进致癌细胞转化。此外,遗传缺乏 PLA2R1 的小鼠显示出对 RAS 诱导的肿瘤发生的敏感性增加,从而促进 OIS 逃逸,突出了其作为肿瘤抑制因子的生理作用。出乎意料的是,PLA2R1 激活了 JAK2 及其效应信号,PLA2R1 介导的细胞转化抑制在 JAK2 耗尽的细胞中基本逆转。这一发现出乎意料,因为 JAK2 途径主要与促肿瘤功能相关,目前有几种抑制剂正在临床试验中。总之,我们的研究结果揭示了 PLA2R1 的一个意想不到的肿瘤抑制作用,该作用是通过靶向下游 JAK2 效应信号介导的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验